These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 9274893)

  • 41. Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience.
    Balk AH; Weimar W; Rothbarth PH; Meeter K; Metselaar HJ; Mochtar B; Simoons ML
    Infection; 1993; 21(4):195-200. PubMed ID: 8225620
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation.
    Hooks MA; Perlino CA; Henderson JM; Millikan WJ; Kutner MH
    Ann Pharmacother; 1992 May; 26(5):617-20. PubMed ID: 1317228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.
    Singh N; Yu VL; Mieles L; Wagener MM; Miner RC; Gayowski T
    Ann Intern Med; 1994 Mar; 120(5):375-81. PubMed ID: 8304654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
    Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Costs and consequences of cytomegalovirus disease.
    Schnitzler MA
    Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S5-8. PubMed ID: 14686228
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.
    Hibberd PL; Tolkoff-Rubin NE; Cosimi AB; Schooley RT; Isaacson D; Doran M; Delvecchio A; Delmonico FL; Auchincloss H; Rubin RH
    Transplantation; 1992 Jan; 53(1):68-72. PubMed ID: 1310173
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors associated with the development of cytomegalovirus infection following solid organ transplantation.
    da Cunha-Bang C; Sørensen SS; Iversen M; Sengeløv H; Hillingsø JG; Rasmussen A; Mortensen SA; Fox ZV; Kirkby NS; Christiansen CB; Lundgren JD
    Scand J Infect Dis; 2011 May; 43(5):360-5. PubMed ID: 21306196
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients.
    DesJardin JA; Cho E; Supran S; Gibbons L; Werner BG; Snydman DR
    Clin Infect Dis; 2001 Oct; 33(8):1358-62. PubMed ID: 11565077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
    Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV
    Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world effectiveness of preemptive therapy (PET) for cytomegalovirus (CMV) disease prevention in CMV high-risk donor seropositive/recipient seronegative (D+R-) liver transplant recipients (LTxR).
    Doss KM; Kling CE; Heldman MR; Singh N; Wagener M; Rakita RM; Fisher CE; Limaye AP
    Transpl Infect Dis; 2023 Apr; 25(2):e14015. PubMed ID: 36734631
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
    Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidence and outcomes of cytomegalovirus in pancreas transplantation with steroid-free immunosuppression.
    Shah AP; Chen JM; Fridell JA
    Clin Transplant; 2015 Dec; 29(12):1221-9. PubMed ID: 26458498
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multicenter evaluation.
    Weir MR; Henry ML; Blackmore M; Smith J; First MR; Irwin B; Shen S; Genemans G; Alexander JW; Corry RJ
    Transplantation; 1988 Jan; 45(1):111-6. PubMed ID: 2827352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
    Burak KW; Kremers WK; Batts KP; Wiesner RH; Rosen CB; Razonable RR; Paya CV; Charlton MR
    Liver Transpl; 2002 Apr; 8(4):362-9. PubMed ID: 11965581
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-Term Impact of Cytomegalovirus Serologic Status on Lung Transplantation in the United States.
    Kurihara C; Fernandez R; Safaeinili N; Akbarpour M; Wu Q; Budinger GRS; Bharat A
    Ann Thorac Surg; 2019 Apr; 107(4):1046-1052. PubMed ID: 30476471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis.
    Arbo MD; Snydman DR; Wong JB; Goldberg HS; Schmid CH; Pauker SG
    Clin Transplant; 2000 Feb; 14(1):19-27. PubMed ID: 10693631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Preemptive Therapy and Antiviral Prophylaxis for Prevention of Cytomegalovirus in Seropositive Liver Transplant Recipients.
    Liu AW; Jutivorakool K; Fisher CE; Rakita RM; Reyes JD; Bhattacharya RB; Jerome KR; Limaye AP
    Transplantation; 2018 Apr; 102(4):632-639. PubMed ID: 29215460
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The association between cytomegalovirus immune globulin and long-term recipient and graft survival following liver transplantation.
    Fisher RA; Kistler KD; Ulsh P; Bergman GE; Morris J
    Transpl Infect Dis; 2012 Apr; 14(2):121-31. PubMed ID: 21883757
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.
    Kim JM; Lee SK; Kim SJ; Joh JW; Kwon CH; Choe YH; Shin M; Kim EY; Moon JI; Jung GO; Choi GS
    Transplant Proc; 2010 Apr; 42(3):895-9. PubMed ID: 20430199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.